CA
DYN icon

Cliff Asness’s Dyne Therapeutics DYN Stock Holding History

Cliff Asness’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Sell
84,054
-184
-0.2% -$3.42K ﹤0.01% 2666
2026
Q1 		$1.53M Buy
84,238
+13,579
+19% +$234K ﹤0.01% 2529
2025
Q4 		$1.38M Sell
70,659
-71,216
-50% -$1.35M ﹤0.01% 2367
2025
Q3 		$1.79M Buy
141,875
+98,965
+231% +$1.13M ﹤0.01% 2038
2025
Q2 		$409K Buy
42,910
+19,350
+82% +$213K ﹤0.01% 2718
2025
Q1 		$246K Buy
+23,560
New +$337K ﹤0.01% 2781
2024
Q4 		– Sell
-89,198
Closed -$3.2M – 2891
2024
Q3 		$3.2M Buy
89,198
+80,703
+950% +$3.21M ﹤0.01% 1262
2024
Q2 		$300K Buy
8,495
+352
+4% +$10.2K ﹤0.01% 2268
2024
Q1 		$231K Buy
+8,143
New +$184K ﹤0.01% 2219
2023
Q4 		– Sell
-11,644
Closed -$104K – 2354
2023
Q3 		$104K Sell
11,644
-8,525
-42% -$91.8K ﹤0.01% 2226
2023
Q2 		$227K Buy
+20,169
New +$238K ﹤0.01% 2047

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Cliff Asness's DYN Position: Q2 2026 in Review

Cliff Asness reduced its Dyne Therapeutics (DYN) stake by 0.22% in Q2 2026, selling an estimated $3.42K and leaving 84,054 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2666.

Cliff Asness first reported a position in DYN in Q2 2023 and has held it in 11 quarters since. The position peaked at $3.2M in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Cliff Asness held 84,054 shares of Dyne Therapeutics worth $1.87M as of Q2 2026.
  • Cliff Asness sold 184 Dyne Therapeutics shares in Q2 2026, an estimated $3.42K.
  • Dyne Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2666 holding.
  • Cliff Asness first reported a position in Dyne Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • Cliff Asness's Dyne Therapeutics position peaked at $3.2M in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.